Tag Archives: COVID-19 Vaccine

Paused: Eli Lilly monoclonal antibody study and J&J COVID-19 vaccine trials

By on .

By Daniel R. Lucey M.D., MPH, FIDSA In the past 24 hours both the Johnson & Johnson Phase 3 single-dose vaccine study, and the Eli Lilly monoclonal antibody study (studies?) have been paused, and their Data-Safety Monitoring Board (DSMB) convened to evaluate safety concern(s). Johnson and Johnson (J&J)  issued a statement saying: “We have temporarily […]

Science, not politics, must lead to COVID vaccine approvals

By on .

Political pressure to speed the introduction of COVID vaccines threatens scientifically proven systems to protect public safety and research integrity The following is a guest post from Uché Blackstock, MD, Founder & CEO, Advancing Health Equity, and Mitchell Warren, Executive Director, AVAC COVID-19 has devastated communities and health systems around the world – but it […]

COVID-19: FDA Emergency Use Authorization for a vaccine in the fall of 2020 means the time for public dialogue is August      

By on .

By Daniel R. Lucey M.D., MPH, FIDSA The only past U.S. Food and Drug Administration Emergency Use Authorization for any vaccine was in January 2005 for the licensed (since 1970) anthrax vaccine to be used in military personnel “for prevention of inhalation anthrax for individuals between 18 and 65 years of age who are deemed […]